Study Summary
This trial is testing a new combination of drugs to treat sarcomas. The drugs are disulfiram (DSF), copper gluconate (Cu), and liposomal doxorubicin. The trial will test the safety of this combination.
- Relapsed Sarcomas
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
5 Primary · 6 Secondary · Reporting Duration: At 2 months
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
DSF/Cu
1 of 1
Experimental Treatment
24 Total Participants · 1 Treatment Group
Primary Treatment: Liposomal Doxorubicin (Doxil) · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age Any Age · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What state do they live in?
| Minnesota | 100.0% |
What site did they apply to?
| Cleveland Clinic, Case Comprehensive Cancer Center | 100.0% |
What portion of applicants met pre-screening criteria?
| Met criteria | 100.0% |
Frequently Asked Questions
Are there opportunities for new enrollees to join this experiment?
"According to the data hosted on clinicaltrials.gov, this research endeavor is not currently recruiting participants; its listing was initially published on December 1st 2022 and most recently edited a little over two months ago. Nevertheless, there are 443 other trials actively enrolling patients at present." - Anonymous Online Contributor
What are the intended objectives of this research project?
"This clinical trial, which is planned to be monitored for a month following the last treatment of subjects, has two main objectives. The primary goal is to document the number of participants who experience Adverse Events categorized as Grade 3 or higher according to CTCAE5.0 standards. Secondary goals include evaluating the pharmacokinetics of DSF/Cu in combination with liposomal doxorubicin through clearance and average steady state concentrations measurements on samples collected from participants; determining median overall survival (OS) and Event free survival times based on RECIST v1.1 criteria; and measuring at least 20% relative increase in target lesions" - Anonymous Online Contributor
Is there any danger associated with taking Liposomal Doxorubicin (Doxil)?
"Liposomal Doxorubicin (Doxil)'s safety is not fully established yet, so we assume a score of 1 on this scale. This indicates that it's currently in its first phase of clinical trials and there is limited evidence regarding effectiveness and safety." - Anonymous Online Contributor